ArriVent Banks $326.4M Cash, ARR-002 IND Cleared, Firmonertinib Data Due Mid-2026
ArriVent reported $326.4 million in cash and investments as of March 31, 2026, funding operations into Q4 2027 with Q1 net cash usage of $41.9 million. The company secured FDA IND clearance for dual-target ADC ARR-002 and expects pivotal firmonertinib EGFR exon 20 data mid-2026.
1. First Quarter 2026 Financial Results
As of March 31, 2026, ArriVent held $326.4 million in cash and investments, providing a cash runway into the fourth quarter of 2027. Net cash used in operations for Q1 was $41.9 million, compared with $68.0 million year-ago, while R&D expenses declined to $37.6 million and G&A expenses rose to $8.5 million, resulting in a net loss of $43.3 million.
2. IND Clearance and Preclinical Data for ARR-002
In May 2026, ArriVent received FDA IND clearance for ARR-002, a dual-target MUC16/NaPi2b tetravalent ADC targeting ovarian and endometrial cancers, and plans to dose the first patient in the second half of 2026. Preclinical presentations at AACR highlighted ARR-002’s superior anti-tumor activity and tolerability compared to single-target and bivalent ADCs in ovarian cancer models.
3. Clinical Progress and Upcoming Catalysts
The company’s pivotal Phase 3 program for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC is underway, with topline monotherapy data expected mid-2026, while the global ALPACCA trial continues enrolling patients. In March 2026, ArriVent dosed the first patient in the ARR-217 Phase 1 trial for gastrointestinal malignancies and aims to complete dose escalation and initiate optimization in the second half of 2026.